FDA approves Amgen and Allergan's KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin ® (trastuzumab)

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Related Links:

Publication date: Available online 15 July 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Lisa M. Bartnikas, Michelle F. Huffaker, William J. Sheehan, Watcharoot Kanchongkittiphon, Carter R. Petty, Robert Leibowitz, Michael C. Young, Wanda Phipatanakul
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: Available online 15 July 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Emad I. Wafa, Sean M. Geary, Kathleen A. Ross, Jonathan T. Goodman, Balaji Narasimhan, Aliasger K. SalemAbstractThe primary objective of this study was to enhance the antitumor efficacy of a model cancer vaccine through co-delivery of pentaerythritol lipid A (PELA), an immunological adjuvant, and a model tumor antigen, ovalbumin (OVA), separately loaded into polyanhydride particles (PA). In vitro experiments showed that encapsulation of PELA into PA (PA-PELA) significantly enhanced its stimulatory capacity on...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
A new study finds that patients with autoimmune disease treated with anti- tumor necrosis factor alpha have an increased risk of developing inflammatory bowel disease.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
Publication date: Available online 14 July 2019Source: Biosensors and BioelectronicsAuthor(s): Maxime Lobry, Driss Lahem, Médéric Loyez, Marc Debliquy, Karima Chah, Mariel David, Christophe CaucheteurAbstractSaccharide sensors represent a broad research area in the scope of sensing devices and their involvement in the medical diagnosis field is particularly relevant for cancer detection at early stage. In that context, we present a non-enzymatic optical fiber-based sensor that makes use of plasmon-assisted tilted fiber Bragg gratings (TFBGs) functionalized for D-glucose biosensing through polydopamine (PDA)-i...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
Publication date: Available online 15 July 2019Source: Journal of Molecular StructureAuthor(s): Mousa Al-Noaimi, Firas F. Awwadi, Wamidh H. Talib, Salem Atia, Hassan H. HammudAbstractPalladium(II) complex [Pd(HL)Cl] (1) (H2L = 2-PhS(C6H4)NH-NC=(COCH3)–NHC6H5) has been synthesized by reacting K2PdCl4 with H2L. The pincer H2L ligand is coordinated to a Pd(II) in an anionic 5π electron form via k3 –SNN to produce neutral 1-trans and 1-cis isomers in the solid state. The structures of two isomers (1-trans and 1-cis) were determined by single crystal X-ray diffraction. Furthermore, complex 1 has been characte...
Source: Journal of Molecular Structure - Category: Molecular Biology Source Type: research
Soft Matter, 2019, Accepted Manuscript DOI: 10.1039/C9SM00541B, PaperAhmet Nihat Simsek, Andrea Braeutigam, Matthias D Koch, Joshua Shaevitz, Yunfei Huang, Gerhard Gompper, Benedikt Sabass Mechanical properties of the extracellular matrix are important determinants of cellular migration in diverse processes, such as immune response, wound healing, and cancer metastasis. Moreover, recent studies indicate that even... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Soft Matter latest articles - Category: Chemistry Authors: Source Type: research
BACKGROUND: The suicide risk was higher in kidney cancer patients than in the general population. The purpose of this study was to characterize the suicide rates among kidney cancer patients and to identify the potential risk factors associated with suicid...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news
Fentanyl is a potent synthetic opioid with a variety of possible applications. Transdermal fentanyl patches are regularly prescribed for patients with severe chronic or cancer-related pain. The potential for abuse is well-known and cases associated with il...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin Third FDA Approval From Amgen's Biosimilars Portfolio THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab):  for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. "...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
In this study, we evaluated whether the combination of focused ultrasound (FUS) and microbubbles can improve adoptively NK-92MI cell infiltration into ovarian tumors through biodistribution, immunofluorescence, and flow cytometry. The treatment effects of using this strategy twice a week were explored. The potential molecular mechanism of FUS assisting NK cell therapy was also initially explored through evaluating the expression of ICAM1 and CX3CL1 by qRT-PCR. Our results indicated that FUS and microbubbles can improve NK-92MI cells’ infiltration into tumors, and the combination of FUS and NK-92MI cells had a better ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Adenocarcinoma | Allergy | Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Pharmaceuticals